Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4
slide-5

E-Ova L 2.5 Tablet

Prescription Icon
Prescription Required

Marketer

Koye Pharmaceuticals Pvt ltd

Salt Composition

Letrozole (2.5mg)

Overview E-Ova L 2.5 Tablet

Post-menopausal women with breast cancer may find relief with E-Ova L 2.5 Tablet. This medication can be administered independently or in conjunction with other therapies, including surgical intervention or radiotherapy. In advanced breast cancer cases, it aids in preventing metastasis. E-Ova L 2.5 Tablet may be ingested with or without food; dosage and duration are determined by the physician to optimize treatment. The prescribed regimen varies depending on the individual's condition and treatment goals. Common side effects, such as increased perspiration, weariness, hot flashes, and elevated cholesterol, should be reported to the physician if they become problematic. Preventive or mitigating strategies may be discussed with your doctor. Prior to commencing treatment, inform your physician of any pre-existing liver or kidney conditions, osteoporosis, or ongoing medications, as these factors can influence efficacy or interact with the medication. Pregnancy or breastfeeding should also be disclosed. Pre- and ongoing treatment may include blood tests assessing vitamin D levels and bone density.

Uses of E-Ova L 2.5 Tablet

Managing breast cancer

Major Benefits of E-Ova L 2.5 Tablet:

Administer this medication precisely as directed by your physician, adhering to the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. E-Ova L 2.5 Tablet can be consumed with or without food, although consistent timing is recommended.

Common Side effects of E-Ova L 2.5 Tablet:

  • Dizziness
  • Fatigue
  • Weakness
  • Bone pain
  • Back pain
  • Night sweats
  • Joint pain
  • Nausea
  • Osteoporosis
  • Joint inflammation
  • Weight gain
  • Hot flushes
  • Edema (swelling)
  • Flushing (sense of warmth in the face, ears, neck and trunk)
  • Diaphoresis
  • Bone fracture
  • Hypercholesterolemia (high cholesterol)
  • Cough
  • Shortness of breath

How to use E-Ova L 2.5 Tablet:

Administer this medication according to your physician's prescribed dosage and schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. E-Ova L 2.5 Tablet can be consumed with or without food, although consistent timing is recommended.

How E-Ova L 2.5 Tablet works:

Estrogen production is reduced by the aromatase inhibitor, E-Ova L 2.5 Tablet. This lowers estrogen levels, potentially hindering or halting the growth of estrogen-dependent breast cancers.

SAFETY ADVICE

AlcoholAlcoholSAFE

There are no known adverse reactions associated with the concomitant ingestion of alcohol and E-Ova L 2.5 Tablet.

PregnancyPregnancyUNSAFE

The use of E-Ova L 2.5 Tablet is strongly contraindicated during pregnancy. Pregnant women should consult their physician, as research in both animal and human studies has revealed substantial risks to fetal development.

Breast feedingBreast feedingUNSAFE

Lactation is contraindicated with E-Ova L 2.5 Tablet due to the potential for infant toxicity.

DrivingDrivingUNSAFE

Taking E-Ova L 2.5 Tablet may cause drowsiness, blurred vision, and dizziness, reducing alertness. Refrain from driving if you experience these effects.

KidneyKidneySAFE IF PRESCRIBED

E-Ova L 2.5 Tablet poses no known safety concerns for individuals with kidney impairment, and dosage modification isn't necessary. Nevertheless, data regarding its use in patients with terminal kidney failure is scarce. Physician consultation is advised.

LiverLiverCAUTION

Patients with hepatic impairment should use E-Ova L 2.5 Tablets cautiously; dosage modification may be necessary. Physician consultation is advised.

What if you forget to take E-Ova L 2.5 Tablet :

Should you forget to take your E-Ova L 2.5 Tablet, administer it immediately upon remembrance. If, however, your next scheduled dose is imminent, omit the missed dose and resume your usual medication timetable. Never take a double dose.

Facts to Know About E-Ova L 2.5 Tablet

LabelValue
Chemical Classification Diphenylmethane derivative
Developing Habits No.
Treatment Category Cancer Drugs

FAQs on E-Ova L 2.5 Tablet

E-Ova L 2.5 Tablets are an aromatase inhibitor, typically prescribed for postmenopausal women with breast cancer, including those who have undergone surgery or chemotherapy.
E-Ova L 2.5 Tablet is an anti-estrogen medication. It works by inhibiting aromatase, an enzyme that produces estrogen, thereby lowering estrogen levels in the body. This is beneficial because estrogen fuels the growth of certain breast cancers, known as estrogen-dependent cancers. Lowering estrogen production can help prevent these cancers from progressing.
For advanced breast cancer or cancer that has spread, continue taking E-Ova L 2.5 Tablet until tumor progression. Following tamoxifen or surgery, continue for five years or until recurrence, whichever occurs first. Alternatively, a sequential regimen of two years of E-Ova L 2.5 Tablet followed by three years of tamoxifen may be used.
It's safe to combine irbesartan with E-Ova L 2.5 Tablet, but monitor your blood pressure closely as E-Ova L 2.5 Tablet might raise it. Consult your doctor if blood pressure management becomes difficult.
While rare, E-Ova L 2.5 Tablet may lead to cataracts. Seek immediate medical attention if you develop blurred vision or eye irritation.
E-Ova L 2.5 Tablet may cause hot flushes, a common side effect from decreased estrogen. These usually lessen as your body adapts, but may persist throughout treatment and subside afterward. If bothersome, consult your doctor for relief.
While rare, E-Ova L 2.5 Tablet may cause serious side effects such as stroke, angina, heart attack, blood clots, cataracts, osteoporosis, and severe skin reactions.
Estrogen deficiency from E-Ova L 2.5 Tablets can lead to bone thinning (osteoporosis). Your doctor may monitor your bone density through testing before, during, and after treatment to detect osteoporosis.
The Ministry of Health and Family Welfare restricts E-Ova L 2.5 Tablet use to ovulation induction in women with anovulatory infertility.
E-Ova L 2.5 Tablet
141
MRP 164
14% off